• Accueil
• mcv4
• CanSinoBIO announces approval for its MCV4 meningococcal vaccine Menhycia in China

CanSinoBIO announces approval for its MCV4 meningococcal vaccine Menhycia in China

4.5 (540) · € 31.99 · En Stock

China's CanSino seeks more vaccine contracts after AstraZenca deal

Meningococcal immunizecanada

Meningococcal immunizecanada

MenQuadfi, Vaccines & biologics, Product Catalog

58160-0955-09, Vaccines & biologics, Product Catalog

Meningococcal immunizecanada

China's CanSino reports 'positive' interim data from COVID mRNA

康希诺生物 CanSinoBIO

康希诺生物 CanSinoBIO

WHO authorizes China's CanSinoBIO COVID-19 vaccine - Global Times

China's CanSino seeks more vaccine contracts after AstraZenca deal

First Vaccine Share In Hong Kong Stock，CanSinoBIO Annou

CanSinoBIO's Covid-19 mRNA vaccine receives clinical trial

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research